Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/8/2013

CRANBURY, N.J., Feb. 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE-MKT: PTN) will announce its second quarter, fiscal year 2013 financial results on Thursday, February 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 14, 2013, which will include discussion of the results of operations in greater detail and an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call / Webcast- 2Q Fiscal Year 2013 Financial Results Press Release

2/14/2013 at 7:30 a.m. ET- 2Q Fiscal Year 2013 Conference Call-Live

2/14/2013 at 11:00 a.m. ET  Domestic Dial-In Number

1-888-539-3678  International Dial-In Number

1-719-325-2329  Passcode

4795478- 2Q Fiscal Year 2013 Conference Call-Replay

2/14/2013-2/21/2013  Domestic Dial-In Number

1-888-203-1112  International Dial-In Number

1-719-457-0820  Passcode

4795478  Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
2. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
4. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
8. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
11. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... identification solutions, today announced its GHS Label Guide . To align chemical ... System (GHS), this guide includes explanations of label components, an example of an ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
(Date:7/29/2015)... ... 29, 2015 , ... Available in select spas and ... nighttime-specific product that targets fat cells for extreme contouring action. During sleep key ... cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat ...
(Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.529 01/2002 , ... , , , , ... , Cell type , Bacteria, gram negative, ...
... / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.526 01/2002 , , , , ... , Microorganism , Nocardia corallina, ... , Bacteria, gram positive, , ...
... , Multiporator , , , , , , , ... Protocol No. 4308 915.048 11/2001 , , , ... , Organism , Neurospora crassa, ... Filamentous fungus, conidia, , , ...
Cached Biology Technology:Pseudomonas putida 2Nocardia corallina 2Neurospora crassa 2
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... WASHINGTON -- A new report released today by ... seafood produced with less damage to the environment. It ... farmed marine fish compare to unlabeled options in the ... designed to help seafood buyers sort through competing sustainability ...
... this week of additional radioactive leaks from Fukushima nuclear ... of radioactivity from the plants remains unclear. But a ... levels of radioactivity discharged from the facility in the ... basic conclusions about the history of contaminant releases to ...
... A study of the wolves of Yellowstone National ... respond to environmental changes. The study, which was ... the Dec. 2, 2011 issue of Science . ... changes in various characteristics of wolves living in the ...
Cached Biology News:New study puts eco-labels to the test 2Researchers assess radioactivity released to the ocean from the Fukushima nuclear facility 2Researchers assess radioactivity released to the ocean from the Fukushima nuclear facility 3Study of Yellowstone wolves improves ability to predict their responses to environmental changes 2Study of Yellowstone wolves improves ability to predict their responses to environmental changes 3
Cyno macaque plasma and serum - various quantities available...
Marmoset plasma and serum - various quantities available...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
Biology Products: